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Abstract
Rationale Impairment in time perception, a critical component of decision-making, represents a risk factor for psychiatric
conditions including substance abuse. A therapeutic that ameliorates this impairment could be advantageous in the treatment
of impulsivity and decision-making disorders.
Objectives Here we hypothesize that the catechol-O-methyltransferase (COMT) inhibitor tolcapone, which increases dopamine
tone in frontal cortex (Ceravolo et al Synapse 43:201–207, 2002), improves time perception, with predictive behavioral, genetic,
and neurobiological components.
Methods Subjects (n = 66) completed a duration estimation task and other behavioral testing in each of two sessions after receiving
a single oral dose of tolcapone (200 mg) or placebo in randomized, double-blind, counterbalanced, crossover fashion. Resting state
fMRI data were obtained in a subset of subjects (n = 40). Subjects were also genotyped for the COMT (rs4680) polymorphism.
Results Time perception was significantly improved across four proximal time points ranging from 5 to 60 s (T(524) = 2.04, p =
0.042). The degree of this improvement positively correlated with subjective measures of stress, depression, and alcohol
consumption and was most robust in carriers of the COMT Val158 allele. Using seed regions defined by a previous meta-
analysis (Wiener et al Neuroimage 49:1728–1740, 2010), we found not only that a connection from right inferior frontal gyrus
(RIFG) to right putamen decreases in strength on tolcapone versus placebo (p < 0.05, corrected), but also that the strength of this
decrease correlates inversely with the increase in duration estimation on tolcapone versus placebo (r = − 0.37, p = 0.02).
Conclusions Compressed time perception can be ameliorated by administration of tolcapone. Additional studies should be con-
ducted to determine whether COMT inhibitors may be effective in treating decision-making disorders and addictive behaviors.
Keywords Dopamine . Time perspective . Time perception . Impulsivity . Treatment
Introduction
Our subjective experience of time shapes our decision-mak-
ing. If a task is perceived as taking a lengthy time to complete,
some will find it hard to wait while others will be unperturbed.
As anyone who has ever taken a long car trip knows, individ-
uals have different thresholds for deciding when to ask, BAre
we there yet?^ Similarly, many find it difficult to persevere in
the face of unanticipated challenges—i.e., to continue despite
obstacles and setbacks and to avoid making impulsive, ulti-
mately disadvantageous decisions. Intriguingly, this type of
temporal impulsivity also contributes to the propensity to de-
velop problems with alcohol, drugs, gambling, overspending,
and overeating (Hamilton et al. 2015; London 2016) and to
the deleterious behavioral consequences of neurodegenerative
diseases such as frontotemporal dementia (Bertoux et al.
2015). Expanding time horizon could potentially enable vul-
nerable individuals to wait longer for appropriate rewards and
thereby improve many decision-making disorders.
Consistent with the important role of dopamine in reward-
based decision-making, several clinical conditions involving
dopaminergic dysfunction are characterized by impaired time
perception, such as stimulant abuse (Wittmann et al. 2007)
and Parkinson’s disease (Jones et al. 2008), suggesting that
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the dopamine system could be fundamentally involved in tem-
poral decision-making (Wiener et al. 2011). Indeed, a number
of investigators have hypothesized that individuals who are
hypo-dopaminergic specifically in frontal regions are most
susceptible to difficulties with accelerated time perception
(Blum et al. 2007; Gold et al. 2015) and by extension are more
likely to develop problems with alcohol and drug abuse
(Conner et al. 2010). In keeping with this idea, varia-
tions in the dopamine-metabolizing enzyme catechol-O-
methyltransferase (COMT), as well as in other dopami-
nergic genes such as DRD2, which encodes the dopa-
mine D2 receptor, have been linked to behavioral dif-
ferences in time perception in healthy controls (Balci et al.
2013; Wiener et al. 2011).
Similarly, differences in time perception are likely to have a
specific neural correlate. A recent meta-analysis of time per-
ception across a variety of tasks and studies (Wiener et al.
2010) demonstrated associated neural activity within two pre-
frontal brain regions, the right inferior frontal gyrus (RIFG)
and the supplemental motor area (SMA). Moreover, greater
activation in lateral prefrontal and striatal regions correlates
with improved time perception (Wiener et al. 2014) and de-
pletion of dopamine precursors leads to impairments in time
perception as well as decreased timing-specific BOLD signal
in the SMA and putamen (Coull et al. 2012). These studies
suggest that increasing dopamine in prefrontal cortex may
correspondingly improve time perception, and that this im-
provement may be mediated by changes in top-down control
over behavior (i.e., via altered connectivity between relevant
prefrontal regions and the striatum). Because the FDA-
approved COMT inhibitor tolcapone acts to preferentially
augment dopamine tone in frontal regions of the brain
(Doudet et al. 1997), this medication may be useful in
assessing this hypothesis, especially as previous work has
shown that tolcapone can improve behavioral self-regulation
and, correspondingly, alter the magnitude of correlations be-
tween frontal and striatal brain areas (Kayser et al. 2012;
Kayser et al. 2017).
Here we investigate whether a single oral dose of the
COMT inhibitor tolcapone alters time perception, and whether
a relationship exists between the effects of tolcapone on mea-
sures of time perception, time perspective, and future orienta-
tion. We additionally assess whether the effects of tolcapone
on measures of time perception are modified by the COMT
Val158Met genotype, a functional polymorphism in the
catecholamine-O-methyltransferase (COMT) gene that im-
pacts frontal cognitive function (Apud et al. 2007; Egan et
al. 2001). As there are well-established relationships between
hazardous alcohol use, behavioral impulsivity, and mood dis-
orders (Dick et al. 2010; Jentsch and Taylor 1999; Koob and
Le Moal 1997), we also assess the degree to which these
behavioral measures correlate with the magnitude of the
tolcapone effect on time perception. Finally, we test whether
tolcapone leads to changes in resting state connectivity in
frontostriatal circuits associated with time perception. Our
overarching aim is to take the first steps to determine whether
a COMT inhibitor could be of therapeutic benefit to popula-
tions suffering from psychiatric conditions that affect deci-
sion-making.
Materials and methods
Subjects
All subjects (n = 66; 33 females) gave written informed con-
sent in accordance with the Human Research Protection
Program (HRPP) at the University of California, San
Francisco, University of California, Berkeley, and
Department of Defense Human Research Protection Office
(HRPO). Subjects underwent a medical history, physical ex-
amination, and blood draw to evaluate liver enzyme levels
prior to completing a number of screening questionnaires,
including the Stanford Time Perspective Inventory (STPI),
the Alcohol Use Disorders Identification Test (AUDIT), the
Depression, Anxiety, and Stress Scale (DASS), the Obsessive
Compulsive Drinking Scale (OCDS), and the Barratt
Impulsiveness Scale (BIS). Subjects were excluded for recent
psychoactive drug use, clinically significant medical or psy-
chiatric illness, liver function tests ≥ 3 times the normal upper
limit, a history of liver disease, regular use of any drugs with
either dopaminergic actions or contraindications for use with
tolcapone, and pregnancy or breastfeeding (females). Subjects
were additionally screened forMRI criteria and were excluded
for any conditions that could render MRI unsafe. Time per-
ception data were collected as part of larger neuropharmacol-
ogy studies conducted at the UCB Brain Imaging Center (be-
low). None of the time perception data contained herein were
used in conjunction with outcome measures from those
studies.
Subjects were administered either 200 mg tolcapone or
placebo in a randomized, double-blind, counterbalanced,
crossover design. This dose of tolcapone was selected based
on our previously published findings indicating that a single
200 mg tolcapone dose produces reliable behavioral results
without significant or consistent side effects (Cameron et al.
2018; Kayser et al. 2012; Kayser et al. 2015; Kayser et al.
2017;Saez et al. 2015). Order was assigned using standard
random allocation sequence-generating software by a study
investigator who did not otherwise have contact with subjects.
Subjects and all study staff who had contact with subjects
were blinded to the intervention: medication bottles were la-
beled with a unique letter for each drug condition and did not
otherwise contain identifiable information. The placebo and
tolcapone capsules were visually identical and were
compounded by a licensed compounding pharmacist together
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with 25 mg of the B vitamin riboflavin in order to mask any
urine discoloration produced by tolcapone. Between 2 and 3 h
after drug administration (i.e., during presumptive peak
tolcapone levels (Deleu et al. 2002; Jorga et al. 2000)), sub-
jects completed a computerized time perception task in which
they were asked to make a key press after they perceived that
specific durations of time had passed (5, 15, 30, and 60 s). The
four time intervals were independently presented. Subjects
were monitored for counting strategies but were not explicitly
told not to count.
To ensure that any effects of tolcapone were not related to
lower level effects on motor responding, subjects also com-
pleted a control task assessing reaction time (RT) (Kayser et
al. 2012; Wittmann and D'Esposito 2015). In brief, subjects
were required to press the space bar as quickly as possible
following the brief appearance of a fixation cross in the center
of an otherwise blank screen. To avoid allowing subjects to
predict the appearance of the fixation cross, the inter-stimulus
interval was jittered between 2000 and 5000ms, with intervals
drawn from a uniform distribution discretized into 50 ms bins.
To reduce the influence of attentional lapses, we cued subjects
with a tone presented between 150 and 750 ms prior to the
appearance of the fixation cross, with the interval drawn from
a uniform distribution discretized into 150 ms bins. Subjects
completed 25 trials over approximately 2 min just prior to
study drug administration and again 3–4 h following drug
administration. The difference between the mean RTs for each
of these instances of the task was compared across drug and
placebo sessions.
At the conclusion of the final study visit, subjects were
asked which visit they believed they had received study drug
and which they had received placebo. Subjects performed at
chance when asked to guess which drug cycle they were on,
suggesting that the subjective effects of tolcapone were not
largely distinguishable from placebo.
To analyze behavior, we pursued two approaches. For one
set of behavioral analyses, we directly evaluated the absolute
difference in seconds between the actual and the desired du-
rations (inaccuracy =Δt). This approach was particularly use-
ful for comparison of temporal task performance with behav-
ioral questionnaires evaluating drug and alcohol use, for
which we focused onΔt values obtained for the 60 s duration,
as previous data indicate that inaccuracy increases over time
(Buhusi and Meck 2005). Because such behavioral question-
naires capture broader time frames than those used here for
time perception testing, we hypothesized that using the lon-
gest time perceptionmeasurement wouldmaximize the oppor-
tunity to identify a relationship between the shorter interval
effects tested here and the longer interval effects assessed by
the questionnaires.
For the other set of analyses, we divided the absolute dif-
ference in seconds between the actual and desired durations
for the duration estimation task by the desired interval in
seconds (inaccuracy =Δt/t). This ratio approach, akin to eval-
uating the Weber fraction (Wittmann et al. 2007), reflects po-
tentially fundamental principles of sensory perception
(Norwich 1987) at the cost of reducing potentially important
duration-specific variance in the data. In addition, by normal-
izing performance across different time intervals, this ap-
proach permitted us to produce an overall estimate for time
perception averaged across the tested durations and to define
the temporal precision of subjects’ estimates in each drug
condition via the standard deviation across the four duration
responses.
fMRI image acquisition and preprocessing
A subset of 40 right-handed subjects also underwent resting
state functional MRI. The remaining subjects could not be
scanned due to subjects’ scheduling constraints and time avail-
able at the imaging facility. MRI scanning was conducted on a
Siemens MAGNETOMTrio 3 TMR Scanner at the Henry H.
Wheeler, Jr. Brain Imaging Center at the University of
California, Berkeley. Anatomical images consisted of 160
slices acquired using a T1-weighted MP-RAGE protocol
(TR = 2300 ms, TE = 2.98 ms, FOV = 256 mm, matrix size =
256 × 256, voxel size = 1 mm3). Three hundred twenty-five
resting state volumes consisting of 24 transverse slices were
acquired over a period of approximately 7.5 min with a gra-
dient echoplanar imaging protocol (325 images, TR =
1370 ms, TE = 27 ms, FOV = 225 mm, matrix size = 96 ×
96, voxel size = 2.3 × 2.3 × 3.5 mm).
FMRI preprocessing was performed using both the AFNI
(http://afni.nimh.nih.gov) and FSL (http://www.fmrib.ox.ac.
uk/fsl) software packages. Functional images were converted
to 4D NIfTI format and corrected for slice-timing offsets.
Motion correction was carried out using the AFNI program
3dvolreg, with the reference volume set to the mean image of
the series. Co-registration was performed with the AFNI pro-
gram 3dAllineate using the local Pearson correlation cost
function optimized for fMRI-to-MRI structural alignment.
The subsequent inverse transformation was used to warp the
anatomical image to the functional image space. Anatomical
and functional images were then normalized to a standard
volume (MNI_N27: 3 mm× 3 mm× 3 mm voxels) using the
FSL program fnirt available from the Montreal Neurological
Institute (MNI; http://www.bic.mni.mcgill.ca) prior to
application of connectivity analyses.
Connectivity analysis
In order to evaluate connectivity between seed regions and
other brain areas, resting state data were smoothed by a 5
mm FWHM Gaussian kernel prior to temporal bandpass fil-
tering between 0.009 and 0.08 Hz to reduce the influence of
cardiac and respiratory artifacts (Fox et al. 2005). Movement
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parameters and the white matter and ventricular time series,
but not the global mean signal, were included as regressors of
no interest. Two regions within the prefrontal cortex, the right
inferior frontal gyrus (RIFG: MNI coordinates [46 7 24]) and
the supplementary motor area (SMA: MNI coordinates [0 -3
59]), were then selected based upon a conversion from
Talairach coordinates provided by a meta-analysis conducted
by Wiener and colleagues (Wiener et al. 2010). By modeling
every stereotactic coordinate as a 3D Gaussian distribution to
test the probability of activation across 41 timing studies con-
taining 446 sets of activation foci, this voxel-wise meta-anal-
ysis determined that the RIFG and SMAwere the only brain
regions with significant voxel activation across all timing
tasks. Each ROI was defined by a set of MNI coordinates that
formed the center for a sphere with 5 mm radius. A time
course determined by averaging across voxels in this region
was then correlated independently with every other voxel in
the brain, and correlation coefficients were Fisher-transformed
to allow for the application of parametric statistical tests.
The so-called standard univariate contrasts were not
possible due to the lack of a contrasting baseline con-
dition and the absence of discrete task epochs. For
whole brain analyses, images were normalized to the
MNI template prior to the application of group-level
statistics. Map-wise significance (p < 0.05, corrected for
multiple comparisons) was determined by applying a
cluster-size correction derived from the AFNI programs
3dFWHMx and 3dClustSim to data initially thresholded
at a value of p < 0.005, uncorrected. Because of our
hypotheses about changes in frontostriatal connectivity,
the volume of a striatal mask (AAL regions 71–76
(Tzourio-Mazoyer et al. 2002)) was used to calculate
the appropriate cluster-size correction of 14 voxels.
Genetics
DNA extraction and SNP analysis were performed by the
Genomics Core at the UCSF Institute for Human Genetics
on salivary samples (salimetrics.com) collected during
the screening visit. DNA was extracted using Gentra
Puregene reagents and protocols and quantified using
the Pico Green method (Molecular Probes/Invitrogen).
Genotyping of the following polymorphisms via polymerase
chain reaction was carried out using TaqMan® technology
(Applied Biosystems): oxytocin receptor (OXTR; rs53576),
oxytocin receptor (OXTR; rs2254298), dopamine D2
receptor (DRD2; rs6277), and catechol-O-methyltransferase
(COMT; rs4680). However, in keeping with the hypothesis
presented here, only the COMT rs4680 data have been
analyzed. Two genetics samples could not be called due to
bacterial contamination and one sample was lost at the
laboratory, leading to a total of 63 samples included in
statistical analysis.
Statistical analysis
As the data set consists of both normally distributed data and
data that did not meet the presumptions of normal distribution,
a combination of parametric and nonparametric statistical tests
were used for analysis. A Scheirer Ray Hare two-factor non-
parametric ANOVA with Tukey HSD post hoc testing was
used to assess differences in drug condition across time.
Two-tailed Mann-Whitney tests were used to evaluate time
differences between genetic samples. For the ratio approach
in which performance was normalized across different time
intervals, parametric tests were used. A linear mixed model
evaluated the difference in the ratio (tolcapone–placebo) as a
function of one fixed effect (duration) and one random effect
(subject) using the Matlab function Bfitlme.^ Pearson’s corre-
lation coefficients were used to calculate statistical signifi-
cance of behavioral measures against drug effect. Because five
behavioral questionnaires were included in comparisons
based on Pearson’s correlation coefficient, we used a
Bonferroni correction to allow for multiple comparisons
(corrected threshold p value = 0.01). Parametric ANOVA
and t test were also used to evaluate the RT data. All statistical
tests were chosen in consultation with the UCSF Biostatistics
Core, were performed using Excel v. 15.22 and MatLab, and
were confirmed at www.Vassarstats.net.
For connectivity analyses of BOLD data, significance was
calculated using statistical techniques and corrections imple-
mented in the AFNI software package, including the functions
3dFWHMx, 3dClustSim, and 3dttest++.
Results
Perception
Following placebo administration, subjects displayed a com-
pressed time perspective at each of the four tested time points,
such that time was perceived as progressing faster than actual
time. This compressed time perspective was attenuated by
administration of a single dose of tolcapone and approached
significance (200 mg; main effect; p = 0.053; F(1) = 3.75; n =
66; Fig. 1). Tukey HSD pairwise comparisons did not reveal
additional significant findings at any of the four individual
time points. When the data were reanalyzed using a factor of
session (first visit versus second visit) rather than drug
(tolcapone versus placebo), the result was not significant
(p = 0.65 (n.s.); F(1) = 0.21, n = 66).
When subjects’ duration estimates were instead analyzed
as a ratio of differences (Δt/t) rather than absolute differences
(see BMaterials and methods^) within a linear mixed mod-
el, the effect of tolcapone was significant (T(524) = 2.04,
p = 0.042). There was no main effect of interval dura-
tion (T(524) = 0.94, p = 0.34 (n.s.)) and no interaction
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between drug and interval (T(524) = 0.08, p = 0.94 (n.s.)).
Additionally, the precision of subjects’ estimates, defined as
the standard deviation of the difference ratios for each of the
four durations, did not differ between tolcapone and placebo
conditions (difference = 0.0004 ± 0.086, T(65) = − 0.034, p =
0.97 (n.s.)). Together these data demonstrate that subjects are
more accurate in their perception of time following tolcapone
administration and suggest that tolcapone is acting to expand
subjective time horizon.
Because tolcapone acts to inhibit the function of the
dopamine-degrading enzyme COMT, we next evaluated
whether the presence of a functional COMT polymorphism
(Val158Met) influenced baseline time perception or response
to tolcapone. COMT genotyping indicated a sample of 24 Val/
Val homozygotes, 27 Met/Val heterozygotes, and 12 Met/Met
homozygotes. A trend for Met homozygotes to be significant-
ly more accurate in their baseline perception of time than
Val carriers did not ultimately reach significance (p = 0.109;
z = − 1.60, n = 63; Figure S1).
To explore whether these findings could be linked to be-
havioral and genetic measures potentially relevant to addictive
and other behaviors, we assessed the relationship of accurate
temporal perception at the longest duration, 60 s (see
BMaterials and methods^), to scores on behavioral question-
naires including the Stanford Time Perspective Inventory
(STPI) and the Alcohol Use Disorders Inventory Test
(AUDIT; see BMaterials and methods^). Variability in base-
line time perception at 60 s correlated significantly with future
time perspective as measured using the STPI (p = 0.042, R =
0.25, t = 2.08, n = 66) suggesting that the effects found here
could extend to future orientation. Stratification by genotype
indicated that the effect of tolcapone at 60 s was carried by
subjects with a Val allele, as it was this group that responded
with significantly improved time perception following
tolcapone administration (p = 0.046; z = − 1.99, n = 63;
Fig. 2). This effect was not, however, seen for the 5 s duration
(p = 0.992; z = 0.01; n = 63).
In keeping with the results for future time perspective, the
size of the tolcapone effect at the 60 s time perception duration
also significantly positively correlated with measures of de-
pression, anxiety, and stress, (DAS; p = 0.004, R = 0.381, t =
2.98, n = 66; BDI = p = 0.006; R = 0.367, t = 2.84, n = 66;
Fig. 3a, b) and with measures of both obsessive-compulsive
alcohol drinking (OCDS; p = 0.0007, R = 0.444, t = 3.58, n =
66; Fig. 3c) and hazardous alcohol consumption (AUDIT; p =
0.003, R = 0.401, t = 3.16; n = 66; Fig. 3d). No significant re-
lationships were found for the 5 s time perspective duration.
Generation of a correlation matrix demonstrated that these
behavioral measures were also highly inter-correlated, with
R values ranging from 0.45 to 0.899 (S6), arguing that they
capture shared behavioral variance.
Surprisingly, the size of the tolcapone effect at 60 s did not
correlate with impulsivity (BIS; p = 0.758, R = − 0.039, t = −
0.31, n = 66), leading us to further stratify subjects based
on second-order factors within the BIS instrument
(attention, motor, perseverance, self-control, cognitive
instability, and cognitive complexity) and COMT geno-
type as well as to stratify subjects using a bi-factor
model (Steinberg et al. 2013) However, further stratification
did not yield significant effects.
Fig. 1 Tolcapone and temporal inaccuracy. The x-axis shows the four
estimated temporal durations, ranging from 5 to 60 s. The y-axis
indicates the difference in the subject’s duration estimate as
compared with the desired duration (termed inaccuracy, in
seconds), where 0.0 represents an exact estimate and negative
numbers indicate that the subject made a key press before the
goal duration had elapsed. Blue bars represent placebo, red bars
represent tolcapone, and gray bars delineate standard error. A
Scheirer Ray Hare two-factor non-parametric ANOVA demonstrates
that compressed time perspective was significantly attenuated by
administration of a single dose of tolcapone (p = 0.053; F(1) =
3.75; n = 66)
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To ensure that the effects of tolcapone on time perception
were not related to non-specific motor effects or to an altered
response threshold, subjects performed a control task in which
they attended to a computer screen for approximately 2 min
and pressed a button as quickly as possible following the
repeated pseudorandom appearance of a fixation cross. To
control for potential RT variations between the two testing
days, we administered this task twice, once before and once
approximately 3 h after drug administration. We then calcu-
lated the mean RT difference (mean RT after medication mi-
nus mean RT before medication) for both the tolcapone and
placebo sessions. There was no significant difference in the
mean RT difference between tolcapone and placebo (mean ±
std dev = 0.7 ± 45.0 ms, T(52) = 0.12, p = 0.91 (ns). There was
also no effect of drug (T(51) = − 1.15, p = 0.26) and no effect
of session (T(51) = 1.1, p = 0.28) on RT and no influence of
genotype on either the effect of drug (F(2,51) = 0.14, p = 0.87)
or the effect of session (F(2,51) = 0.09, p = 0.91).
fMRI
A seminal meta-analysis of time perception (Wiener et al.
2010) identified the right inferior frontal gyrus (RIFG) and
supplementary motor area (SMA) as the two brain regions
activated in response to a variety of timing conditions across
a number of published motor and perceptual tasks. Using
these two areas as seed regions and assuming a basal ganglia
mask to assess our hypothesis regarding changes in
corticostriatal connectivity, we found that a connection from
RIFG to the right putamen significantly decreased in strength
on tolcapone versus placebo across all subjects (Fig. 4a, p <
0.05, corrected; R putamen cluster (cluster size = 16) with
MNI coordinates x = 33, y = 6, z = 5; peak T value = 3.63;
peak p value = 0.00081). No other significant findings were
seen when we expanded our search to the rest of the brain, and
no significant results were seen for the SMA seed (data not
shown). To assess whether the magnitude of the change in
strength of this connection covaried with our behavioral re-
sults, we used the ratio of the change in time perception to the
desired duration,Δt/t (see BMaterials andMethods^), to com-
pute a mean change value for each subject across all four
durations. Intriguingly, the magnitude of the decrease in
corticostriatal connectivity between the RIFG and R putamen
correlated inversely with the increase in duration estimation
on tolcapone versus placebo (p = 0.02, R = − 0.37,
bootstrapped confidence interval [− 0.59, − 0.023], t = −
2.45, n = 40; Fig. 4b). These data remained significant when
analyzed using a non-parametric test to reduce the influence of
individual data points (Kendall’s tau = − 0.185, p = 0.047).
Discussion
We have previously demonstrated that the COMT inhibitor
tolcapone reduces impulsive decision-making in a delay
discounting paradigm (Kayser et al. 2012). Consistent with
the hypothesized role of dopamine in component processes
related to impulsivity and brain circuitry, we now show that
compressed time perspective can be ameliorated by a single
dose of the COMT inhibitor tolcapone, and that these effects
cannot be explained by session effects or changes in low-level
motor responding. Moreover, we found a significant positive
correlation between temporal accuracy at a short time interval
(specifically, 60 s) and a more protracted measure of future
orientation, suggesting both that the measures of time percep-
tion collected here may indeed be pertinent to a far longer time
Fig. 2 COMT genotype and the effects of tolcapone on time perception.
The x-axis includes the three Val158Met genotypes (Met/Met, Met/Val,
and Val/Val). The y-axis indicates inaccuracy (placebo-tolcapone), in
seconds. A Mann-Whitney test demonstrated a significant difference in
drug effect on time perception between COMT genotypes at 60 s (p =
0.046, z = − 1.99, n = 63). Gray bars delineate standard error
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horizon (see Grondin 2010), and that augmenting frontal do-
pamine tone could be useful in enabling vulnerable subject
populations to develop a more accurate sense of time.
These findings are consistent with previous work that eval-
uated the influence of dopamine on time perception. In keep-
ing with our current results demonstrating the possible benefit
of increasing frontal dopamine tone, a past study found that
dopamine depletion in healthy subjects impaired the accuracy
of time perception, most likely by attenuating neural activity
in the supplementary motor area and putamen that is hypoth-
esized to be important for initiating storage of temporal infor-
mation into working memory (Coull et al. 2012). Similarly,
the seminal behavioral work of Rammsayer (Coull et al. 2011;
Rammsayer 1997a, 1997b) demonstrated that D2-receptor an-
tagonists impair interval discrimination at sub- and
suprasecond durations. Notably, no effects of L-dopa, a dopa-
mine precursor, on duration discrimination were seen
(Rammsayer 1989a, 1989b), emphasizing the potential
importance of the brain region in which increased do-
pamine tone is occurring (diffuse in response to L-dopa,
more specifically cortical/frontal with tolcapone). Taken to-
gether, these data suggest that individuals who are functional-
ly hypodopaminergic at baseline have an attenuated time ho-
rizon and impaired time perception that might be improved by
increasing dopamine availability in frontal regions.
The passage of time is typically underestimated both in
healthy control subjects and in patient populations (Buhusi
and Meck 2005; Harrington et al. 1998; Peterburs et al.
2013). Our current data are consistent with the Vierordt effect,
which describes a baseline tendency to underestimate time
a
b
c
d
Fig. 3 Tolcapone and behavioral/emotional measures. For all plots, the x-
axis includes the questionnaire score, and the y-axis indicates the
difference in the duration estimate, in seconds, for the placebo condition
minus the tolcapone condition. There is a significant positive correlation
(Pearson’s correlation coefficient) between drug effect on time perception
at 60 s and depression, anxiety, and stress measured using the DASS (a,
Pearson’s p = 0.004, R = 0.381, t = 2.98, n = 66) as well as a significant
positive correlation between drug effect on time perception at 60 s and
depression measured using the BDI (b, Pearson’s p = 0.006, R = 0.367,
t = 2.84, n = 66). There is a significant positive correlation between drug
effect on time perception at 60 s and obsessive-compulsive
drinking measured using the OCDS (c, Pearson’s p = 0.0007,
R = 0.444, t = 3.58, n = 66) as well as a significant positive
correlation between drug effect on time perception at 60 s and
hazardous drinking measured using the AUDIT (d, Pearson’s p =
0.003, R = 0.401. t = 3.16, n = 66)
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durations longer than approximately 5 s (Bausenhart et al.
2014; Peterburs et al. 2013; Shi et al. 2013). Taken together,
the present results extend the abovementioned findings by
demonstrating that increasing frontal tone can improve time
perception, and they suggest that the potential of tolcapone to
generate more accurate time perception in some subjects
might be mediated by a reduction in the perceived Bslowness^
of time.
Our results are also consistent with past work evaluating
the effect of polymorphisms in dopamine-related genes. In
keeping with a myriad of previous reports related to impulsiv-
ity and executive control (e.g., Grant et al. 2015; Schacht
2016), the data presented here suggest that a genetic polymor-
phism in the protein target of tolcapone, COMT, may contrib-
ute to altered time perception. Recent findings have demon-
strated, for example, that COMTVal158Met Val/Val homozy-
gotes express greater variability on a suprasecond timing as-
sessment (Wiener et al. 2011). A subsequent study by this
same group showed that Met carriers displayed reduced mem-
ory variability in this same suprasecond time window (Balci et
al. 2013). Our current data suggest that individuals with at
least one copy of the Val allele are more likely to exhibit a
compressed time horizon at baseline and to display the most
obvious improvement in time perception following tolcapone
administration. However, because of the small sample size
and limited power of the current dataset, additional studies
are necessary to fully assess the effects of tolcapone by
genotype.
Considering the above pharmacological and genetic data,
the cognitive mechanisms by which tolcapone may improve
time perception are most likely located in cortical and
corticostriatal circuitry. Importantly, the results of the studies
described in the preceding paragraphs occurred primarily at
suprasecond as opposed to subsecond durations, a time frame
that is thought to engage cortically based cognitive processes.
Based on these data, it has been proposed that increases in
cortical dopamine tone might reduce memory variance and
increase the fidelity of working memory encoding (Balci et
al. 2013; Coull et al. 2012). In addition, dopamine denotes
events as salient (Berridge and Robinson 1998; Robinson
and Berridge 1993; Salamone and Correa 2012) and is neces-
sary for both assigning credit to available choices (Cockburn
et al. 2014) and facilitating action selection (Bogacz et al.
2007). By influencing a connection between RIFG and stria-
tum, dopamine might initiate a working memory trace that can
be used as a time stamp for credit assignment and for encoding
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Fig. 4 Connectivity and time
perception. a The connection
from RIFG to the right putamen
decreased in strength on
tolcapone versus placebo across
all subjects, as indicated by the
cool/blue color (p < 0.05,
corrected; R putamen cluster
(cluster size = 16) with MNI
coordinates x = 33, y = 6, z = 5;
peak T value = 3.63; peak p
value = 0.00081). b The strength
of the decrease in corticostriatal
connectivity between the RIFG
and R putamen (x-axis) correlated
inversely with the increase in
duration estimation (y-axis) on
tolcapone versus placebo
(Pearson’s p = 0.02, R = − 0.37,
t = − 2.45, n = 40)
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and remembering credit assignment to facilitate future action
selection. Perhaps by robustly marking an event as salient,
dopamine increases the depth of temporal and motivational
encoding via the RIFG and encourages the memory of these
salient events over longer time durations.
That tolcapone led to a decrease, rather than an increase, in
connectivity between the RIFG and the putamen deserves
further consideration. At least two possibilities exist. First, a
nearby, potentially overlapping, region of the RIFG has been
shown to play a pivotal role in inhibitory control; specifically,
it is commonly activated when subjects perform tasks requir-
ing intermittent unexpected inhibition of planned actions, as in
the stop signal paradigm (reviewed in Aron et al. 2014).While
controversy continues to exist about the cognitive process
instantiated by this region—i.e., whether it implements an
inhibitory Bstop signal^ itself or whether it is part of a larger
network that provides a more general monitoring function
(Hampshire and Sharp 2015)—attenuation of its connectivity
with the putamenmay reduce the pressure to stop the temporal
estimation process, thereby permitting a longer duration time
estimate. Alternatively, because of the inverted U-shaped re-
sponse to dopamine tone in many frontal regions (Cools and
D'Esposito 2011), it is possible that decreased connectivity
between RIFG and putamen reflects a decline in attention
related to too much, rather than too little, dopamine tone.
Because reductions in attention are known to prolong duration
estimates (Coull et al. 2004; Mangels et al. 1998), tolcapone’s
action may represent an adverse effect that nonetheless ap-
pears as a behavioral improvement. This hypothesis would
be consistent with data showing that impaired connectivity
between the IFG and striatum is associated with executive
dysfunction (Quan et al. 2013).
If this latter possibility is true, then a decline in working
memory or a change in a related function, counting, would not
easily explain our other results with tolcapone, which include
reductions in the discounting of delayed rewards (Kayser et al.
2012), increases in goal-directed exploration (Kayser et al.
2015), and more altruistic distribution of resources (Saez et
al. 2015). Moreover, we did not see changes in a control task
that required sustained attention for the intermittent appear-
ance of a fixation cross. While we were unable to directly
control for the use of subvocal rehearsal (such as counting)
as a strategy to assist subjects in assessing the passage of time,
previous research has shown that counting does not improve
accuracy within the temporal window used in our time per-
ception task (Hinton et al. 2004; Thönes and Hecht 2017).
Nonetheless, addressing these hypotheses would clearly ben-
efit from future experiments to directly evaluate task-related
(as opposed to resting state) neural changes, as well as relevant
tests of working memory.
Irrespective of the underlying cognitive mechanisms, the
changes we observed within the corticostriatal circuitry that
processes temporal information correlated with scores on
instruments that assess behaviors associated with changes in
dopamine functioning. The current data show, for example,
that the effects of tolcapone on temporal impulsivity may be
most beneficial in those with affective disorders, as evaluated
by questionnaires addressing stress, anxiety, and depression
and comorbid alcohol use disorder (AUD). Significant rela-
tionships were seen with both the AUDIT and obsessive-
compulsive drinking scales at the 60 s time duration, raising
the possibility that tolcapone might contribute in particular to
the treatment of AUD. However, contrary to our initial hy-
pothesis, the size of the tolcapone effect on time perception
did not correlate with impulsivity as measured by the Barratt
Impulsiveness Score (BIS). Because we previously reported
greater levels of impulsivity in individuals with alcohol use
disorder (Mitchell et al. 2005; Mitchell et al. 2007), we decid-
ed to further classify the current subject population based on
their level of alcohol consumption (median split by AUDIT
score), as it is possible that the relationship between impulsiv-
ity and drinking that we previously reported in subjects with
AUDs would not be present in low drinking subjects. Testing
homogeneity of the two resulting regressions indicated a trend
towards significance (p = 0.057, F = 3.77, n = 66), suggesting
that there may be a difference in the relationship between
impulsivity and the effect of tolcapone on time perception in
hazardous drinkers as compared to those who drink within the
normal range. It is therefore possible that this difference in
subgroups blunted our ability to appropriately study the rela-
tionship between impulsivity and the effects of a COMT in-
hibitor on time perception.
The present data were collected from a group of young,
generally healthy, and ethnically diverse subjects who had
volunteered to participate in neuroimaging and pharmacology
studies in a university setting. As such, these data may not
completely characterize the population at large, nor be indic-
ative of temporal processing in an older group of individuals.
Additional studies would be needed to determine how the
effects of frontal dopamine on time perception change as we
age. More broadly, as additional behavioral and neurological
factors emerge that predict the temporal effects of increased
frontal dopamine tone, these can be used to characterize
groups that will most benefit from administration of a
COMT antagonist.
In summary, previous research indicates that lower frontal
dopamine levels result in poorer executive control (Boettiger
et al. 2007; Gallagher et al. 2015) and difficulties with impul-
sivity and time perception (Blum et al. 2007; Gold et al. 2015).
Our current findings suggest that compressed time perception,
a hypothesized component of impulsivity (Peters and Buchel
2011), can be improved by administration of the COMT in-
hibitor tolcapone, perhaps by decreasing connectivity between
RIFG and R putamen. If replicated, the data reported here
could be relevant to individuals suffering from a number of
clinical conditions that are characterized by deficits in time
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perception. Further studies could then determine whether
COMT inhibitors might be therapeutically effective in treating
psychiatric conditions, such as alcohol and substance abuse,
that are linked to perturbations in time perception and deci-
sion-making.
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